Nektar Therapeutics (NKTR) Misses Q1 EPS by 69c, Miss on Revenues
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $74.90 +2.39%
EPS Growth %: +26.6%
Financial Fact:
Provision for income taxes: 139K
Today's EPS Names:
EPAC, SAR, KRUS, More
EPS Growth %: +26.6%
Financial Fact:
Provision for income taxes: 139K
Today's EPS Names:
EPAC, SAR, KRUS, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.60), $0.69 worse than the analyst estimate of $0.09. Revenue for the quarter came in at $38.02 million versus the consensus estimate of $140.61 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kura Sushi (KRUS) Tops Q3 EPS by 3c; offers outlook
- Raymond James Starts Old National Bancorp (ONB) at Market Perform
- TaiMed Biologics gets TFDA drug license notice for HIV therapy Trogarzo
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
